Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HARPNASDAQ:LIANNASDAQ:PHXMNASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/ALIANLianBio$0.20$0.20$0.27▼$4.99$21.61M0.231.04 million shs2,652 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AZBIOZenas Biopharma$7.93+17.0%$0.00$5.83▼$26.25$331.47MN/A200,225 shs179,459 shs10 Stocks Set to Soar in Spring 2025Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%LIANLianBio0.00%+0.10%0.00%-23.98%-35.61%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%ZBIOZenas Biopharma+16.96%+2.85%+792,999,900.00%+792,999,900.00%+792,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHARPHarpoon Therapeutics0.6521 of 5 stars0.00.00.04.70.62.50.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHARPHarpoon Therapeutics 0.00N/AN/AN/ALIANLianBio 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/AZBIOZenas Biopharma 3.00Buy$40.00404.41% UpsideCurrent Analyst Ratings BreakdownLatest HARP, ZBIO, LIAN, and PHXM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025ZBIOZenas BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$35.003/12/2025ZBIOZenas BiopharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12LIANLianBioN/AN/AN/AN/A$2.71 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39ZBIOZenas Biopharma$5M66.29N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/AZBIOZenas BiopharmaN/A-$3.55N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHARPHarpoon TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AZBIOZenas Biopharma$0.050.61%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHARPHarpoon TherapeuticsN/A1.891.89LIANLianBioN/A10.0610.06PHXMPHAXIAM Therapeutics0.231.78N/AZBIOZenas BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHARPHarpoon Therapeutics74.01%LIANLianBio74.85%PHXMPHAXIAM Therapeutics0.40%ZBIOZenas BiopharmaN/AInsider OwnershipCompanyInsider OwnershipHARPHarpoon Therapeutics17.00%LIANLianBio7.59%PHXMPHAXIAM Therapeutics1.94%ZBIOZenas BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableLIANLianBio110108.06 million99.86 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataZBIOZenas BiopharmaN/A41.80 millionN/AN/AHARP, ZBIO, LIAN, and PHXM HeadlinesRecent News About These CompaniesZenas Biopharma (ZBIO) vs. Its Peers Critical ReviewApril 12 at 2:55 AM | americanbankingnews.comHead to Head Contrast: Zenas Biopharma (ZBIO) and Its RivalsApril 12 at 2:55 AM | americanbankingnews.comHead to Head Comparison: Zenas Biopharma (ZBIO) & The CompetitionApril 12 at 2:05 AM | americanbankingnews.comROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOApril 11 at 4:00 PM | accessnewswire.comZenas Biopharma (ZBIO) vs. Its Peers Head to Head ReviewApril 11 at 3:15 AM | americanbankingnews.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRSApril 10 at 4:00 PM | globenewswire.comZenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsApril 10 at 3:00 PM | globenewswire.comZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOApril 9 at 6:59 PM | prnewswire.comZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOApril 9 at 6:59 PM | prnewswire.comZenas Biopharma (ZBIO) & The Competition Financial AnalysisApril 9 at 1:05 AM | americanbankingnews.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOApril 8, 2025 | accessnewswire.comZenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 CatalystApril 7, 2025 | seekingalpha.comZenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific OfficerApril 7, 2025 | globenewswire.comROSEN, A RANKED AND LEADING FIRM, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIOApril 6, 2025 | accessnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIOApril 5, 2025 | accessnewswire.comZenas Biopharma (ZBIO) vs. Its Rivals Head-To-Head ComparisonApril 5, 2025 | americanbankingnews.comZenas Biopharma (ZBIO) versus Its Peers Critical SurveyApril 5, 2025 | americanbankingnews.comZenas Biopharma (ZBIO) & The Competition Critical ContrastApril 5, 2025 | americanbankingnews.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Quantum Computing Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QUBTApril 4, 2025 | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Game of Silks NFT Investors to Secure Counsel Before Important Deadline in Securities Class ActionApril 4, 2025 | globenewswire.comQ1 Earnings Forecast for Zenas Biopharma Issued By WedbushMarch 24, 2025 | marketbeat.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesSpace Stocks Bottoming: Which Are Positioned Best for a Bounce?By Ryan Hasson | March 25, 2025View Space Stocks Bottoming: Which Are Positioned Best for a Bounce?Palantir Setting Up to Be a Big Winner With New Defense SpendingBy Chris Markoch | March 26, 2025View Palantir Setting Up to Be a Big Winner With New Defense SpendingJoby Aviation Stock: Virgin Atlantic Deal Signals Big PotentialBy Jeffrey Neal Johnson | March 18, 2025View Joby Aviation Stock: Virgin Atlantic Deal Signals Big PotentialIntel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesOccidental’s Billion-Dollar Carbon Credit Plan Takes ShapeBy Jea Yu | March 26, 2025View Occidental’s Billion-Dollar Carbon Credit Plan Takes ShapeHARP, ZBIO, LIAN, and PHXM Company DescriptionsHarpoon Therapeutics NASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.LianBio NASDAQ:LIAN$0.20 0.00 (0.00%) As of 04/10/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 04/9/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Zenas Biopharma NASDAQ:ZBIO$7.93 +1.15 (+16.96%) As of 04/11/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
